Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced on November 16, 2026, that additional data from its Phase 1b CANYON-1 clinical trial of CRB-913 were presented at ObesityWeek 2026 in Washington, D.C. The study evaluated CRB-913, an oral, non-incretin therapy, across three dose levels in obese, non-diabetic adults.

The trial enrolled 254 participants at 15 U.S. sites. Participants received a daily oral dose of 20 mg, 40 mg, or 60 mg, or a placebo, over a 12-week treatment period. The data demonstrated statistically significant and clinically meaningful weight loss at all dose levels, with the highest dose (60 mg) achieving a mean weight loss of 5.0% at week 12. Placebo-adjusted weight loss for the 60 mg cohort was 5.0%.

Among the 62 participants in the 60 mg cohort, 44.4% lost at least 5.0% of their body weight, and 6.7% lost more than 7.5%. The highest recorded weight loss in this group was 13.4%. The drug also produced dose-dependent reductions in waist circumference and body mass index (BMI).

Safety data indicated a favorable tolerability profile. The treatment discontinuation rate due to adverse events (AEs) across all cohorts was 8.3%. Treatment-emergent psychiatric AEs were infrequent and mostly mild; only one participant reported moderate depressive symptoms. No serious or severe psychiatric AEs were reported. Gastrointestinal AEs, such as nausea and diarrhea, occurred at lower rates than those typically seen in oral GLP-1 studies.

Corbus stated that these results support CRB-913’s potential as a new class of oral obesity medicine. The company plans to engage with the FDA to discuss the data and development plans. Additionally, Corbus is evaluating the potential for CRB-913 in combination with GLP-1 therapies.